ECSP10010717A - Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina - Google Patents

Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Info

Publication number
ECSP10010717A
ECSP10010717A EC2010010717A ECSP10010717A ECSP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC 2010010717 A EC2010010717 A EC 2010010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A
Authority
EC
Ecuador
Prior art keywords
dosage form
pharmaceutical dosage
immediate release
indoline derivative
methyl
Prior art date
Application number
EC2010010717A
Other languages
English (en)
Inventor
Roman Messerschmid
Peter Lach
Torsten Sokoliess
Peter Stopfer
Dirk Trommeshauser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010717(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010717A publication Critical patent/ECSP10010717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Surgery (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una forma de dosificación farmacéutica que suministra un perfil de liberación inmediata que contiene la sustancia activa 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato.
EC2010010717A 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina ECSP10010717A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157750 2008-06-06

Publications (1)

Publication Number Publication Date
ECSP10010717A true ECSP10010717A (es) 2011-02-28

Family

ID=41017080

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010717A ECSP10010717A (es) 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Country Status (35)

Country Link
US (3) US20110190318A1 (es)
EP (1) EP2313087B2 (es)
JP (2) JP5583119B2 (es)
KR (1) KR20110022586A (es)
CN (1) CN102056599A (es)
AR (1) AR072060A1 (es)
AU (1) AU2009254556B2 (es)
BR (1) BRPI0913235A2 (es)
CA (1) CA2726648A1 (es)
CL (1) CL2010001362A1 (es)
CO (1) CO6280468A2 (es)
CY (1) CY1121272T1 (es)
DK (1) DK2313087T4 (es)
EA (1) EA201001857A1 (es)
EC (1) ECSP10010717A (es)
ES (1) ES2711913T5 (es)
FI (1) FI2313087T4 (es)
HR (1) HRP20190181T4 (es)
HU (1) HUE042524T2 (es)
IL (1) IL209055A0 (es)
LT (1) LT2313087T (es)
MA (1) MA32386B1 (es)
MX (1) MX338001B (es)
PE (1) PE20100050A1 (es)
PL (1) PL2313087T5 (es)
PT (1) PT2313087T (es)
RS (1) RS58280B2 (es)
SG (1) SG191607A1 (es)
SI (1) SI2313087T2 (es)
TR (1) TR201901579T4 (es)
TW (1) TW201002692A (es)
UA (1) UA107560C2 (es)
UY (1) UY31876A (es)
WO (1) WO2009147220A1 (es)
ZA (1) ZA201007972B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
HRP20180709T1 (hr) * 2008-06-06 2018-06-15 Boehringer Ingelheim International Gmbh Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6453319B2 (ja) 2013-06-04 2019-01-16 モノソル リミテッド ライアビリティ カンパニー 水溶性フィルムシール溶液、関連する方法、および関連する物品
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
MX393691B (es) 2015-06-06 2025-03-24 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
JP2020512364A (ja) * 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
BR112020003973A2 (pt) 2017-10-23 2020-09-01 Boehringer Ingelheim International Gmbh combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild)
DK3761980T3 (da) 2018-03-07 2024-01-29 Pliant Therapeutics Inc Aminosyreforbindelser og fremgangsmåder til anvendelse
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
JP2025525881A (ja) 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
SI1948180T1 (sl) 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
SI2985025T1 (en) * 2008-06-06 2018-04-30 Boehringer Ingelheim International Gmbh A pharmaceutical combination
HRP20180709T1 (hr) * 2008-06-06 2018-06-15 Boehringer Ingelheim International Gmbh Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
EP2387401A1 (en) * 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429520A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
HRP20190181T1 (hr) 2019-03-22
CN102056599A (zh) 2011-05-11
JP5583119B2 (ja) 2014-09-03
IL209055A0 (en) 2011-01-31
MX338001B (es) 2016-03-30
DK2313087T3 (en) 2019-02-18
TW201002692A (en) 2010-01-16
AR072060A1 (es) 2010-08-04
SG191607A1 (en) 2013-07-31
CL2010001362A1 (es) 2011-05-13
ES2711913T3 (es) 2019-05-08
KR20110022586A (ko) 2011-03-07
PL2313087T3 (pl) 2019-05-31
RS58280B1 (sr) 2019-03-29
AU2009254556B2 (en) 2015-08-20
US20130203773A1 (en) 2013-08-08
HUE042524T2 (hu) 2019-07-29
JP2011522010A (ja) 2011-07-28
SI2313087T1 (sl) 2019-03-29
ZA201007972B (en) 2011-07-27
CA2726648A1 (en) 2009-12-10
UA107560C2 (uk) 2015-01-26
CO6280468A2 (es) 2011-05-20
US20140163040A1 (en) 2014-06-12
HRP20190181T4 (hr) 2024-07-05
ES2711913T5 (es) 2024-06-24
MX2010013092A (es) 2011-02-25
BRPI0913235A2 (pt) 2016-01-19
UY31876A (es) 2010-01-29
CY1121272T1 (el) 2020-05-29
EP2313087A1 (en) 2011-04-27
PT2313087T (pt) 2019-02-15
JP5992937B2 (ja) 2016-09-14
FI2313087T4 (fi) 2023-12-28
JP2014098045A (ja) 2014-05-29
PE20100050A1 (es) 2010-01-29
PL2313087T5 (pl) 2024-03-04
TR201901579T4 (tr) 2019-02-21
US20110190318A1 (en) 2011-08-04
WO2009147220A1 (en) 2009-12-10
MA32386B1 (fr) 2011-06-01
EA201001857A1 (ru) 2011-06-30
AU2009254556A1 (en) 2009-12-10
RS58280B2 (sr) 2024-02-29
SI2313087T2 (sl) 2024-03-29
EP2313087B2 (en) 2023-11-22
LT2313087T (lt) 2019-02-25
EP2313087B1 (en) 2018-11-21
DK2313087T4 (da) 2024-01-15

Similar Documents

Publication Publication Date Title
ECSP10010717A (es) Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina
ECSP10010660A (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspención de un derivado de indolinona
DOP2012000051A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
FR2928836B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
UY32299A (es) Composiciones farmacéuticas líquidas
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
TN2010000555A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
CU23604B7 (es) Compuestos terapéuticos
CY1114956T1 (el) Νεες συνθεσεις 1-[2-(2,4-διμεθυλο-φαινυλοσουλφανυλο)-φαινυλο]πιπεραζινης